RHYTHM PHARMACEUTICALS, INC. (RYTM) - Dilution Analysis

10-Q filing | 68.0M shares outstanding

10-Q filing | 66.3M shares outstanding

10-Q filing | 63.7M shares outstanding

8-K filing: Rhythm Pharmaceuticals, Inc. completed an offering of 2,058,824 shares of common stock at $85.00 per share, and the underwriters exercised their option to purchase an additional 308,823 shares, resulting in expected net proceeds of approximately $188.7 million. ($175.0M proceeds)

10-Q filing | 63.1M shares outstanding

10-K filing | 61.0M shares outstanding

10-Q filing | 61.2M shares outstanding

10-Q filing | 61.0M shares outstanding

8-K filing: Rhythm Pharmaceuticals filed a prospectus supplement related to the resale of up to 3,124,995 shares of common stock by certain stockholders, satisfying registration rights granted in connection with the issuance and sale of 150,000 shares of Series A Convertible Preferred Stock for $150,000,000 on April 15, 2024. ($150.0M proceeds)

10-Q filing | 60.1M shares outstanding

8-K filing: Rhythm Pharmaceuticals, Inc. completed the issuance and sale of 150,000 shares of Series A Convertible Preferred Stock to affiliates of Perceptive Advisors LLC and other investors for an aggregate purchase price of $150,000,000, or $1,000 per share, and filed the Certificate of Designations with the Secretary of State of the State of Delaware, effective April 15, 2024. ($150.0M proceeds)

8-K filing: Rhythm Pharmaceuticals, Inc. entered into an Investment Agreement for the issuance and sale of 150,000 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $150,000,000. ($150.0M proceeds)

10-K filing | 57.7M shares outstanding

10-Q filing | 57.9M shares outstanding

8-K filing: Rhythm Pharmaceuticals, Inc. sold approximately 2.019 million shares of its common stock in the ATM Program between August 10, 2023 and August 21, 2023 for gross proceeds of approximately $50.0 million. ($50.0M proceeds)

10-Q filing | 56.9M shares outstanding

10-Q filing | 56.7M shares outstanding

10-K filing | 52.1M shares outstanding

10-Q filing | 51.4M shares outstanding

8-K filing: Rhythm Pharmaceuticals, Inc. entered into an underwriting agreement for the issuance and sale of 4,800,000 shares of common stock at a price of $26.00 per share, with the offering expected to close on or about September 19, 2022. ($116.9M proceeds)

10-Q filing | 50.4M shares outstanding

10-Q filing | 50.3M shares outstanding

10-K filing | 49.6M shares outstanding

S-3 filing: Rhythm Pharmaceuticals, Inc. files an S-3 to offer and sell up to $300,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants, and units from time to time in one or more offerings, and also offers common stock in an at the market offering through Cowen and Company LLC.

10-Q filing | 50.3M shares outstanding

10-Q filing | 50.2M shares outstanding

10-Q filing | 48.5M shares outstanding

10-K filing | 44.2M shares outstanding

10-Q filing | 44.2M shares outstanding

10-Q filing | 44.1M shares outstanding

10-Q filing | 44.1M shares outstanding

10-K filing | 44.1M shares outstanding